Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome

Clinical Chemistry

Volumn 60, Issue 1, 2014, Pages 222-232

  Meng, Qing H ^a   Xu, Enping ^a   Hildebrandt, Michelle A T ^a   Liang, Dong ^b   Lu, Karen ^a   Ye, Yuanqing ^a   Wagar, Elizabeth A ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 14; FIBROBLAST GROWTH FACTOR 18; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 5; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KERATINOCYTE GROWTH FACTOR;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84891819848     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.211490     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63: 11-30.
2. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee opinion no. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117: 742-6.
3. Baldwin LM, Trivers KF, Matthews B, Andrilla CH, Miller JW, Berry DL, et al. Vignette-based study of ovarian cancer screening: Do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med 2012;156: 182-94.
4. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79. (Pubitemid 352777353)
5. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al., for the PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305: 2295-303.
6. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010;42: 874-9.
7. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry- Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009; 41: 996-1000.
8. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010;42: 880-4.
9. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, et al. GWAS metaanalysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45:362-70, 70e1-2.
10. Bolton KL, Ganda C, Berchuck A, Pharaoh PD, Gayther SA. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med 2012;271: 366-78.
11. Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 2007;107:S223-9. (Pubitemid 47487477)
12. Yin J, Lu K, Lin J, Wu L, Hildebrandt MA, Chang DW, et al. Genetic variants in TGF- pathway are associated with ovarian cancer risk. PLoS One 2011;6:e25559.
13. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, et al. Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res 2010;70: 9765-76.
14. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012;18: 1855-62.
15. Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 1997;3: 1137-40. (Pubitemid 27444457)
16. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10: 116-29.
17. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011;437: 199-213.
18. Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol 2010;117: 125-9.
19. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, et al. Identification of FGFR4 as a potential therapeutic target for advancedstage, high-grade serous ovarian cancer. Clin Cancer Res 2013;19: 809-20.
20. Madsen CV, Steffensen KD, Olsen DA, Waldstrøm M, Søgaard CH, Brandslund I, Jakobsen A. Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors. Anticancer Res 2012;32: 3817-25.
21. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, Mes-Masson AM. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006;118: 1750-8. (Pubitemid 43376439)
22. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, et al. Whole genome oligonucleotidebased array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. Clin Oncol 2007;25: 2281-7. (Pubitemid 46954656)
23. Smith G, Ng MT, Shepherd L, Herrington CS, Gourley C, Ferguson MJ, Wolf CR. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer 2012;107: 1327-36.
24. Murphy T, Darby S, Mathers ME, Gnanapragasam VJ. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 2010;220: 452-60.
25. Abdel-Rahman WM, Kalinina J, Shoman S, Eissa S, Ollikainen M, Elomaa O, et al. Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous -catenin. Hum Mutat 2008;29: 390-7. (Pubitemid 351364941)
26. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121: 230-8.
27. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 2011;17: 6130-9.
28. Johnatty SE, Beesley J, Chen X, Spurdle AB, Defazio A, Webb PM, et al. Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the Ovarian Cancer Association Consortium. Twin Res Hum Genet 2009;12: 269-75.
29. Zhang H, Singer BH. Recursive partitioning and applications. 2nd ed. New York: Springer; 2010.
30. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100: 9440-5. (Pubitemid 37033947)
31. Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE, et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010;26: 2474-6.
32. Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis - new insights into epithelialstromal interactions. Cancer Cell 2007;12: 495-7. (Pubitemid 350199077)
33. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, Witte ON. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007;12: 572-85. (Pubitemid 350199069)
34. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8: 235-53.
35. Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001;20: 5878-87. (Pubitemid 32937957)
36. Cole C, Lau S, Backen A, Clamp A, Rushton G, Dive C, et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 2010;10: 495-504.
37. Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, et al. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res 2005;11: 4282-8. (Pubitemid 40825614)
38. Steele IA, Edmondson RJ, Leung HY, Davies BR. Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors 2006;24: 45-53. (Pubitemid 43108775)
39. Byron SA, Loch DC, Pollock PM. Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. Int J Gynecol Cancer 2012;22: 1517-26.
40. Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE, et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet. 2012;8:e1002639.